The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 6, 2011, Pages 1471-1478

  Chew, Sin Chi ^a   Singh, Onkar ^b   Chen, Xiangai ^b   Ramasamy, Rathi Devi ^b   Kulkarni, Tejal ^b   Lee, Edmund J D ^a   Tan, Eng Huat ^b   Lim, Wan Teck ^b   Chowbay, Balram ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Asians; Docetaxel; Nasopharyngeal cancer; Pharmacogenetics; Polymorphisms

Indexed keywords

DOCETAXEL; GENOMIC DNA; HEMOGLOBIN;

ABCB1 GENE; ABCC2 GENE; ABCG2 GENE; ADULT; AGED; ALLELE; AREA UNDER THE CURVE; ARTICLE; ASIAN; CONTROLLED STUDY; CYP3A4 GENE; CYP3A5 GENE; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; GENE; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SLCO1B3 GENE;

ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; ATP-BINDING CASSETTE TRANSPORTERS; CYTOCHROME P-450 CYP3A; FEMALE; HUMANS; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NASOPHARYNGEAL NEOPLASMS; NEOPLASM PROTEINS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; TAXOIDS;

EID: 79959579746     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1625-9     Document Type: Article

References (25)

1. Oshiro C, Marsh S, McLeod H et al (2009) Taxane pathway. Pharmacogenet Genomics 19:979-983
2. Wang D, Guo Y, Wrighton S et al (2010) Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. doi:10.1038/tpj.2010.28
3. Hamada A, Sissung T, Price DK et al (2008) Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res 14:3312-3318
4. Imai Y, Nakane M, Kage K et al (2002) C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141 K protein and low-level drug resistance. Mol Cancer Ther 1:611-616
5. Letschert K, Keppler D, König J et al (2004) Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics 14:441-452 (Pubitemid 38971234)
6. Amirimani B, Ning B, Deitz AC et al (2003) Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ Mol Mutagen 42:299-305 (Pubitemid 38054375)
7. Kuehl P, Zhang J, Lin Y et al (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391 (Pubitemid 32268418)
8. Hoffmeyer S, Burk O, von Richter O et al (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glyco-protein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473-3478 (Pubitemid 30183327)
9. Hitzl M, Drescher S, van der Kuip H et al (2001) The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 11:293-298 (Pubitemid 32537402)
10. Miura M, Satoh S, Inoue K et al (2007) Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol 63:1161-1169 (Pubitemid 350112768)
11. Chowbay B, Zhou S, Lee EJD et al (2005) An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: experience in Singapore. Drug Metab Rev 37:327-378 (Pubitemid 40677508)
12. Ngeow J, Lim WT, Leong SS et al (2010) Docetaxel is effective in heavily pretreated patients with disseminated nasopharyngeal carcinoma. Ann Oncol. doi:10.1093/annonc/mdq425
13. Loos WJ, Verweij J, Nooter K et al (1997) Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 693:437-441 (Pubitemid 27250307)
14. Baker SD, Verweij J, Cusatis GA et al (2009) Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther 85:155-163
15. Cascorbi I, Gerloff T, Johne A et al (2001) Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69:169-174 (Pubitemid 32225417)
16. de Jong FA, Marsh S, Mathijssen RHJ et al (2004) ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin Cancer Res 10:5889-5894 (Pubitemid 39180970)
17. Bosch TM, Huitema ADR, Doodeman VD et al (2006) Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin Cancer Res 12:5786-5793 (Pubitemid 44629610)
18. Lewis LD, Miller AA, Rosner GL et al (2007) A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. Clin Cancer Res 13:3302-3311 (Pubitemid 46944916)
19. Tran A, Jullien V, Alexandre J et al (2006) Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther 79:570-580
20. Zeigler-Johnson C, Friebel T, Walker AH et al (2004) CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer. Cancer Res 64:8461-8467
21. Sissung T, Baum C, Deeken J et al (2008) ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin Cancer Res 14:4543-4549
22. Wagner-Souza K, Diamond H, Ornellas M et al (2008) Rhodamine 123 efflux in human subpopulations of hematopoietic stem cells: comparison between bone marrow, umbilical cord blood and mobilized peripheral blood CD34+ cells. Int J Mol Med 22:237-242
23. Kiyotani K, Mushiroda T, Kubo M et al (2008) Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci 99:967-972 (Pubitemid 351997599)
24. Brooks TA, Kennedy DR, Gruol DJ et al (2004) Structure-activity analysis of taxane-based broad-spectrum multidrug resistance modulators. Anticancer Res 24:409-416
25. Jada SR, Lim R, Wong CI et al (2007) Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C > A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci 98:1461-1467